Crown Bioscience Expands Cardiovascular and Metabolic Disease Capabilities
News Oct 15, 2015
Crown bioscience has announced that it has entered an exclusive preclinical services alliance utilizing the world’s largest collection of naturally occurring diabetic translational models.
“Our translational models give sponsors a high level of confidence when deciding to move a drug candidate into clinical development by providing insights into the pharmacological mechanisms of a drug and identifying biomarkers important to clinical trial design,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience.
The models are designed for research involving cardiovascular and metabolic diseases, including spontaneous developed diabetes and its complications, such as diabetic nephropathy, left ventricular diastolic dysfunction, fatty liver, diet-induced dyslipidemia, etc. They were developed to mirror aspects of human disease related to obesity, nephropathy, hyperglycemia, hyperinsulinemia, dyslipidemia, glucose intolerance, reduced glucose disposition, insulin resistance and late stage insulin dependency.
In addition, the company announced that Zhen Pang, M.D., a recognized expert in transgenic models, has joined Crown Bioscience as scientific director. Before joining Crown, Pang held key positions as principal research investigator at several global biopharmaceutical companies, working in metabolic diseases as well as a variety of therapeutic areas.
“We are experiencing substantial growth in demand for our cardiovascular and metabolic disease (CVMD) services because of our depth and capability in cardiovascular and diabetic research,” said Jim Wang, M.D., senior vice president of CVMD research at Crown Bioscience. “With the expansion of our CVMD program in the U.S. and China, as well as the appointment of Dr. Pang, we are able to provide cutting-edge translational platforms and cost-effective drug development solutions to top pharmaceutical companies worldwide.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018